In short
Clinical trials are investigating AUR200 in people with generalized myasthenia gravis. The studies are looking at safety, tolerability, and whether AUR200 can improve daily function in this condition. The trial data describe an interventional, placebo-controlled study in adults with generalized myasthenia gravis.
Key points
- AUR200 is being studied in a clinical trial for people with generalized myasthenia gravis. The study is interventional, randomized, double-blind, and placebo-controlled. It is authorised and includes 51 participants. The trial looks first at safety and tolerability, then at early efficacy, using treatment-emergent adverse events and MG-ADL score change as main measures. The data describe AUR200 given by subcutaneous injection in comparison with placebo.
Trial overview
This clinical trial is studying AUR200 in people with generalized myasthenia gravis, a condition that causes muscle weakness in many parts of the body. The study is designed to look at both safety and early signs that the treatment may help with daily life in this disease.
Study design and treatment groups
The trial is described as a double-blind, randomized, placebo-controlled study. This means people are assigned by chance to a study group, and neither the participant nor the study team knows who receives AUR200 or placebo during the study.
The intervention is given by subcutaneous injection, which means an injection under the skin. The source data list AUR200 and a placebo-like comparison treatment as the study interventions.
Who can participate
The trial is for patients with generalized myasthenia gravis. The source data do not provide more detailed entry rules, so exact eligibility depends on the study screening process.
What researchers are measuring
In Phase 1, the main outcome is the incidence of treatment-emergent adverse events, which means how often new health problems or worsening health problems happen after treatment starts. This part of the study is focused on safety and tolerability.
The brief summary also describes a Phase 2 part that looks at efficacy, which means whether the treatment works. The main Phase 2 outcome is the change from baseline in MG-ADL total score, a measure of how much myasthenia gravis affects daily activities such as speaking, chewing, and walking.
Trial status and size
The study status is Authorised. The planned enrollment is 51 participants, which means the trial is designed to include 51 people in total.
Because this is a small early-stage study, the main goal is to learn whether AUR200 can be studied safely in this patient group and whether there are early signs of benefit.